Comparison of Two Liraglutide Formulations in Healthy Volunteers

Sponsor
Novo Nordisk A/S
Study ID
NCT01508897
Phase
PHASE1
Status
Completed

Conditions

  • Diabetes
  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Single dose administered as subcutaneous injection
  • liraglutide — DRUG
    Single dose administered as subcutaneous injection

Study Details

This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of two formulations of liraglutide.

Key Dates

Start date
May 28, 2004
Status verified
Feb 2017
Primary completion
Jun 30, 2004
Completion
Jun 30, 2004

Study Design

Enrollment
22 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 2 formulation
  • Experimental: Phase 3 formulation

Primary Outcome Measure

Area under the Curve (AUC) (0-t)

Related Studies